Jounce Therapeutics, Inc.
JNCEDelisted May 4, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001640455
Jounce Therapeutics, Inc. was delisted on May 4, 2023; its insiders filed their last Form 4 on May 5, 2023; 84 institutions reported holding it in 13F filings for Q1 2023, worth $64.1M in total; no superinvestor held it.
Q2 2021 vs. Q1 2021
How the institutions holding Jounce Therapeutics, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 124 | 130 | +6 |
| Shares | 36.8M | 36.0M | −820.6K (−2.2%) |
| Value | $378.3M | $244.8M | −$133.5M (−35.3%) |
New holders (20)
Institutions that held Jounce Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Assenagon Asset Management S.A. | 682,870 | $4.64M | 0.02% |
| D. E. Shaw & Co., Inc. | 78,923 | $537.0K | 0.00% |
| Ziegler Capital Management, LLC | 71,097 | $483.0K | 0.02% |
| Jump Financial, LLC | 60,942 | $414.0K | 0.04% |
| Pathway Capital Management, LP | 60,279 | $410.0K | 0.16% |
| Gsa Capital Partners LLP | 52,623 | $358.0K | 0.04% |
| M&G Investment Management Ltd | 36,779 | $257.0K | 0.00% |
| First Quadrant L P | 37,800 | $257.0K | 0.03% |
| Susquehanna Fundamental Investments, LLC | 33,794 | $230.0K | 0.00% |
| Trexquant Investment LP | 33,322 | $227.0K | 0.02% |
| XTX Topco Ltd | 29,928 | $204.0K | 0.07% |
| Engineers Gate Manager LP | 24,500 | $167.0K | 0.01% |
| Mass General Brigham, Inc | 19,291 | $131.0K | 0.03% |
| Hussman Strategic Advisors, Inc. | 15,500 | $105.0K | 0.02% |
| Fiduciary Trust Co | 13,230 | $90.0K | 0.00% |
| Advisory Alpha, LLC | 12,005 | $82.0K | 0.01% |
| Hancock Whitney Corp | 11,664 | $79.0K | 0.00% |
| Prelude Capital Management, LLC | 11,400 | $78.0K | 0.00% |
| Invesco Ltd. | 11,148 | $76.0K | 0.00% |
| MML Investors Services, LLC | 10,000 | $68.0K | 0.00% |
Sold out (14)
Institutions that held Jounce Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Caas Capital Management LP | 1,052,437 | $10.8M |
| Avoro Capital Advisors LLC | 555,000 | $5.70M |
| Asymmetry Capital Management, L.P. | 520,858 | $5.35M |
| Maven Securities LTD | 70,396 | $707.0K |
| Atom Investors LP | 54,762 | $562.0K |
| Standard Life Aberdeen plc | 23,735 | $291.0K |
| Dynamic Technology Lab Private Ltd | 14,827 | $152.0K |
| Ameriprise Financial Inc | 12,000 | $123.0K |
| Manufacturers Life Insurance Company, The | 11,555 | $119.0K |
| Bender Robert & Associates | 10,000 | $103.0K |
| Lazard Asset Management LLC | 5,453 | $56.0K |
| Capital Investment Advisors, LLC | 3,000 | $31.0K |
| Steward Partners Investment Advisory, LLC | 1,600 | $16.4K |
| Sowell Financial Services LLC | 51 | $0 |